Vincent Capponi - 04 Apr 2023 Form 4 Insider Report for Cytosorbents Corp (CTSO)

Role
President and Chief Operating Officer
Signature
/s/ Kathleen P. Bloch attorney-in-fact for Vincent Capponi
Issuer symbol
CTSO
Transactions as of
04 Apr 2023
Net transactions value
+$28,750
Form type
4
Filing time
05 Apr 2023, 19:06:04 UTC
Previous filing
12 Aug 2022
Next filing
11 Jul 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CTSO Common Stock Options Exercise $28,750 +10,000 +2% $2.88 511,989 04 Apr 2023 Direct F1, F2, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CTSO Stock Option (right to buy) Options Exercise $0 -10,000 -100% $0.000000* 0 04 Apr 2023 Common Stock 10,000 $2.88 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Includes (a) the following restricted stock units ("RSUs") that will be settled into common stock, par value $0.001 per share (the "Common Stock") upon vesting upon a "Change In Control" of CytoSorbents Corporation (the "Company") as defined in the Amended and Restated CytoSorbents Corporation 2014 Long-Term Incentive Plan (the "Plan"): (a) 10,100 RSUs granted on March 15, 2018, (b) 17,900 RSUs granted on February 24, 2017, (c) 54,000 RSUs granted on June 7, 2016 and (d) 125,000 RSUs granted on April 8, 2015;
F2 (continued from footnote 2) (b) the following RSUs (which vest as to one-third of the award on each of the date of grant, the first anniversary of the date of grant, and the second anniversary of the date of grant, subject to the reporting person's continued service as of the applicable vesting date) and will settle into Common Stock upon vesting: (a) 20,739 RSUs granted on April 12, 2021 and unvested on the date hereof and (b) 46,000 RSUS granted on August 10, 2021 and unvested on the date hereof ; and
F3 (continued from footnote 3) (c) 238,250 shares of Common Stock owned by the reporting person, inclusive of the 10,000 shares reported on this Form 4.
F4 These stock options were originally granted on April 4, 2013 and became exercisable at the discretion of the Board of Directors of the Company upon the achievement of certain milestones connected to the Company's operations.

Remarks:

President and Chief Operating Officer